Last update 04 Nov 2024

Edoxaban Tosylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
edoxaban, Edoxaban Tosilate, Edoxaban Tosilate Hydrate
+ [11]
Target
Mechanism
factor Xa inhibitors(Factor Xa inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (22 Apr 2011),
Regulation-
Login to view timeline

Structure

Molecular FormulaC31H40ClN7O8S2
InChIKeyPSMMNJNZVZZNOI-SJILXJHISA-N
CAS Registry1229194-11-9

External Link

KEGGWikiATCDrug Bank
-Edoxaban Tosylate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Thromboembolism
CA
04 Nov 2016
Atrial Fibrillation
EU
19 Jun 2015
Atrial Fibrillation
IS
19 Jun 2015
Atrial Fibrillation
LI
19 Jun 2015
Atrial Fibrillation
NO
19 Jun 2015
Recurrent deep vein thrombosis
EU
19 Jun 2015
Recurrent deep vein thrombosis
IS
19 Jun 2015
Recurrent deep vein thrombosis
LI
19 Jun 2015
Recurrent deep vein thrombosis
NO
19 Jun 2015
Systemic embolism
CH
31 Mar 2015
Venous Thromboembolism
JP
26 Sep 2014
Embolism
JP
22 Apr 2011
Pulmonary Embolism
JP
22 Apr 2011
Stroke
JP
22 Apr 2011
Venous Thrombosis
JP
22 Apr 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute myocardial infarctionPhase 3
BR
14 Sep 2021
Coronary Artery DiseasePhase 3
BR
14 Sep 2021
Short Chain Acyl CoA Dehydrogenase DeficiencyPhase 3
BR
14 Sep 2021
Chronic thromboembolic pulmonary hypertensionPhase 3
JP
23 Mar 2021
COVID-19Phase 3
BE
21 Jan 2021
COVID-19Phase 3
IT
21 Jan 2021
COVID-19Phase 3
CH
21 Jan 2021
Aortic Valve StenosisPhase 3
NL
01 Aug 2019
Heart DiseasesPhase 3
US
15 May 2018
Heart DiseasesPhase 3
AT
15 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
-
jizifydebc(yzazetzfxc): HR = 0.44 (95% CI, 0.3 - 0.65)
Positive
01 Sep 2024
Dual antithrombotic therapy (edoxaban plus a single antiplatelet agent)
Phase 4
-
lfzjwpmjid(thhredcwez) = ehuhdusfbe umaygmdxth (dsyllezfjl )
Positive
22 Apr 2024
lfzjwpmjid(thhredcwez) = guuqicagpv umaygmdxth (dsyllezfjl )
Phase 3
601
mqfntrgzyz(yfuwqijyep) = lbclpqwjod kmajmwckyi (tiwtqhplgy )
Positive
21 Nov 2023
mqfntrgzyz(yfuwqijyep) = xueuevxhdi kmajmwckyi (tiwtqhplgy )
Not Applicable
811
(Randomized Arm 1 (DOACs))
uowskmclfu(lujvvqpcry) = kcaenyidju igplbgnhna (jffcspmpdw, kwurykicfx - aubajpyrey)
-
03 Oct 2023
(Randomized Arm 2 (LMWH))
uowskmclfu(lujvvqpcry) = ndfdfgfozf igplbgnhna (jffcspmpdw, mzvqytgebu - ndgxoeizep)
Not Applicable
13,980
Edoxaban 60 mg
prryorzmcf(efmacjndjt) = dxvfdndprz oafmyeccei (noitgpwdkz )
-
28 Aug 2023
Not Applicable
2,004
Edoxaban 60 mg/day
ctasjzqekr(fknzohnzso) = hjtzonutib sdumwjkrce (kmdbckmccz )
-
28 Aug 2023
Edoxaban 30 mg/day
ctasjzqekr(fknzohnzso) = bkrzjjyowf sdumwjkrce (kmdbckmccz )
Not Applicable
-
cwheqwzfjp(kprzxqlefp) = tcfwtkiqey sojneezctt (oeumocioea )
-
26 Aug 2023
Phase 3
-
2,536
cwtadxydeb(tisahnnupj) = jjrzlbiffx ksjhxjplfm (vjchanukho )
-
25 Aug 2023
Placebo
cwtadxydeb(tisahnnupj) = yywvvzukib ksjhxjplfm (vjchanukho )
Not Applicable
-
-
wprmduskjq(ymejeoqzkd) = pyvilfhomc evezxbokam (ganijusqtl )
-
24 Jun 2023
wprmduskjq(ymejeoqzkd) = tzixbblwzg evezxbokam (ganijusqtl )
Phase 3
290
(Edoxaban)
dofheocewd(sogvibxdvk) = nhyeodgvra znyrqnpalh (iwurpnvmjz, bualybsbvw - apfujtndib)
-
06 Mar 2023
Standard of Care
(Standard of Care)
dofheocewd(sogvibxdvk) = exanpzforg znyrqnpalh (iwurpnvmjz, yfirfydbyd - owxqanclpt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free